Common and rare side-effects of low-dose thalidomide in multiple myeloma: Focus on the dose-minimizing peripheral neuropathy

Massimo Offidani, Laura Corvatta, Monica Marconi, Lara Malerba, Anna Mele, Attilio Olivieri, Marino Brunori, Massimo Catarini, Marco Candela, Debora Capelli, Mauro Montanari, Serena Rupoli, Pietro Leoni

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Objectives: Thalidomide has demonstrated a remarkable efficacy in the treatment of multiple myeloma but its use may cause several toxicities. We have investigated the common and rare side-effects, especially analysing peripheral neuropathy, in order to optimise the thalidomide dose for minimizing this harmful side-effect. Methods: Fifty-nine patients were treated with thalidomide alone or combined with oral melphalan. The median age was 69 yr. The initial dose of thalidomide was 100 mg/day increasing weekly by 100 mg increments until a maximum dose of 400 mg was attained. Melphalan was administered at a dose of 0.20 mg/kg/d for 4 d every 28 d. Results and conclusions: Nearly one-fourth of patients discontinued thalidomide because of toxicity. Constipation (71%), somnolence (36%) and fatigue (20%) were the most common side-effects and they were not dose dependent. Peripheral neuropathy occurred in 39% of patients and a thalidomide median daily dose of more than 150 mg was significantly associated with higher frequency and actuarial risk of peripheral neuropathy without improving the response rate. Deep venous thrombosis was observed in 7% of patients and other side-effects were rare. In patients with advanced multiple myeloma we found that a thalidomide daily dose of 150 mg minimizes peripheral neuropathy without jeopardizing response and survival.

Original languageEnglish
Pages (from-to)403-409
Number of pages7
JournalEuropean Journal of Haematology
Volume72
Issue number6
DOIs
Publication statusPublished - Jun 2004

Fingerprint

Thalidomide
Peripheral Nervous System Diseases
Multiple Myeloma
Melphalan
Constipation
Venous Thrombosis
Fatigue
Survival

Keywords

  • Dose
  • Multiple myeloma
  • Side-effects
  • Thalidomide

ASJC Scopus subject areas

  • Hematology

Cite this

Common and rare side-effects of low-dose thalidomide in multiple myeloma : Focus on the dose-minimizing peripheral neuropathy. / Offidani, Massimo; Corvatta, Laura; Marconi, Monica; Malerba, Lara; Mele, Anna; Olivieri, Attilio; Brunori, Marino; Catarini, Massimo; Candela, Marco; Capelli, Debora; Montanari, Mauro; Rupoli, Serena; Leoni, Pietro.

In: European Journal of Haematology, Vol. 72, No. 6, 06.2004, p. 403-409.

Research output: Contribution to journalArticle

Offidani, M, Corvatta, L, Marconi, M, Malerba, L, Mele, A, Olivieri, A, Brunori, M, Catarini, M, Candela, M, Capelli, D, Montanari, M, Rupoli, S & Leoni, P 2004, 'Common and rare side-effects of low-dose thalidomide in multiple myeloma: Focus on the dose-minimizing peripheral neuropathy', European Journal of Haematology, vol. 72, no. 6, pp. 403-409. https://doi.org/10.1111/j.1600-0609.2004.00238.x
Offidani, Massimo ; Corvatta, Laura ; Marconi, Monica ; Malerba, Lara ; Mele, Anna ; Olivieri, Attilio ; Brunori, Marino ; Catarini, Massimo ; Candela, Marco ; Capelli, Debora ; Montanari, Mauro ; Rupoli, Serena ; Leoni, Pietro. / Common and rare side-effects of low-dose thalidomide in multiple myeloma : Focus on the dose-minimizing peripheral neuropathy. In: European Journal of Haematology. 2004 ; Vol. 72, No. 6. pp. 403-409.
@article{ec7fcdeaa80d417ea288e781aca8cc0d,
title = "Common and rare side-effects of low-dose thalidomide in multiple myeloma: Focus on the dose-minimizing peripheral neuropathy",
abstract = "Objectives: Thalidomide has demonstrated a remarkable efficacy in the treatment of multiple myeloma but its use may cause several toxicities. We have investigated the common and rare side-effects, especially analysing peripheral neuropathy, in order to optimise the thalidomide dose for minimizing this harmful side-effect. Methods: Fifty-nine patients were treated with thalidomide alone or combined with oral melphalan. The median age was 69 yr. The initial dose of thalidomide was 100 mg/day increasing weekly by 100 mg increments until a maximum dose of 400 mg was attained. Melphalan was administered at a dose of 0.20 mg/kg/d for 4 d every 28 d. Results and conclusions: Nearly one-fourth of patients discontinued thalidomide because of toxicity. Constipation (71{\%}), somnolence (36{\%}) and fatigue (20{\%}) were the most common side-effects and they were not dose dependent. Peripheral neuropathy occurred in 39{\%} of patients and a thalidomide median daily dose of more than 150 mg was significantly associated with higher frequency and actuarial risk of peripheral neuropathy without improving the response rate. Deep venous thrombosis was observed in 7{\%} of patients and other side-effects were rare. In patients with advanced multiple myeloma we found that a thalidomide daily dose of 150 mg minimizes peripheral neuropathy without jeopardizing response and survival.",
keywords = "Dose, Multiple myeloma, Side-effects, Thalidomide",
author = "Massimo Offidani and Laura Corvatta and Monica Marconi and Lara Malerba and Anna Mele and Attilio Olivieri and Marino Brunori and Massimo Catarini and Marco Candela and Debora Capelli and Mauro Montanari and Serena Rupoli and Pietro Leoni",
year = "2004",
month = "6",
doi = "10.1111/j.1600-0609.2004.00238.x",
language = "English",
volume = "72",
pages = "403--409",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "6",

}

TY - JOUR

T1 - Common and rare side-effects of low-dose thalidomide in multiple myeloma

T2 - Focus on the dose-minimizing peripheral neuropathy

AU - Offidani, Massimo

AU - Corvatta, Laura

AU - Marconi, Monica

AU - Malerba, Lara

AU - Mele, Anna

AU - Olivieri, Attilio

AU - Brunori, Marino

AU - Catarini, Massimo

AU - Candela, Marco

AU - Capelli, Debora

AU - Montanari, Mauro

AU - Rupoli, Serena

AU - Leoni, Pietro

PY - 2004/6

Y1 - 2004/6

N2 - Objectives: Thalidomide has demonstrated a remarkable efficacy in the treatment of multiple myeloma but its use may cause several toxicities. We have investigated the common and rare side-effects, especially analysing peripheral neuropathy, in order to optimise the thalidomide dose for minimizing this harmful side-effect. Methods: Fifty-nine patients were treated with thalidomide alone or combined with oral melphalan. The median age was 69 yr. The initial dose of thalidomide was 100 mg/day increasing weekly by 100 mg increments until a maximum dose of 400 mg was attained. Melphalan was administered at a dose of 0.20 mg/kg/d for 4 d every 28 d. Results and conclusions: Nearly one-fourth of patients discontinued thalidomide because of toxicity. Constipation (71%), somnolence (36%) and fatigue (20%) were the most common side-effects and they were not dose dependent. Peripheral neuropathy occurred in 39% of patients and a thalidomide median daily dose of more than 150 mg was significantly associated with higher frequency and actuarial risk of peripheral neuropathy without improving the response rate. Deep venous thrombosis was observed in 7% of patients and other side-effects were rare. In patients with advanced multiple myeloma we found that a thalidomide daily dose of 150 mg minimizes peripheral neuropathy without jeopardizing response and survival.

AB - Objectives: Thalidomide has demonstrated a remarkable efficacy in the treatment of multiple myeloma but its use may cause several toxicities. We have investigated the common and rare side-effects, especially analysing peripheral neuropathy, in order to optimise the thalidomide dose for minimizing this harmful side-effect. Methods: Fifty-nine patients were treated with thalidomide alone or combined with oral melphalan. The median age was 69 yr. The initial dose of thalidomide was 100 mg/day increasing weekly by 100 mg increments until a maximum dose of 400 mg was attained. Melphalan was administered at a dose of 0.20 mg/kg/d for 4 d every 28 d. Results and conclusions: Nearly one-fourth of patients discontinued thalidomide because of toxicity. Constipation (71%), somnolence (36%) and fatigue (20%) were the most common side-effects and they were not dose dependent. Peripheral neuropathy occurred in 39% of patients and a thalidomide median daily dose of more than 150 mg was significantly associated with higher frequency and actuarial risk of peripheral neuropathy without improving the response rate. Deep venous thrombosis was observed in 7% of patients and other side-effects were rare. In patients with advanced multiple myeloma we found that a thalidomide daily dose of 150 mg minimizes peripheral neuropathy without jeopardizing response and survival.

KW - Dose

KW - Multiple myeloma

KW - Side-effects

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=2542635663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542635663&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2004.00238.x

DO - 10.1111/j.1600-0609.2004.00238.x

M3 - Article

C2 - 15128418

AN - SCOPUS:2542635663

VL - 72

SP - 403

EP - 409

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 6

ER -